These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11511459)

  • 1. The PSA: one test with three uses.
    Harv Mens Health Watch; 2001 Jul; 5(12):1-4. PubMed ID: 11511459
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PSA kinetics after total prostatectomy].
    Riedinger JM; Eche N; Fulla Y; Thuillier F
    Ann Biol Clin (Paris); 2009; 67(1):39-46. PubMed ID: 19189884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinics in prostate cancer].
    Sugimura Y
    Rinsho Byori; 2004 Jul; 52(7):604-10. PubMed ID: 15344560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
    Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
    BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PSA conundrum.
    Vikram B
    Radiother Oncol; 2004 Apr; 71(1):1-2. PubMed ID: 15066289
    [No Abstract]   [Full Text] [Related]  

  • 10. Rising prostate specific antigen after radical prostatectomy: a case based review.
    Nasr R; Goldenberg SL
    Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy.
    Tombal B; Van Cangh PJ; Loric S; Gala JL
    Prostate; 2003 Aug; 56(3):163-70. PubMed ID: 12772185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing intervals for PSA test.
    Douglas M; Strelnick A
    J Fam Pract; 1997 Aug; 45(2):101. PubMed ID: 9267362
    [No Abstract]   [Full Text] [Related]  

  • 13. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 15. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A guideline to clinical utility of prostate specific antigen.
    Farhat WA; Habbal AA; Khauli RB
    Saudi Med J; 2000 Mar; 21(3):223-7. PubMed ID: 11533789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update].
    Graefen M
    Aktuelle Urol; 2004 Sep; 35(5):377-8. PubMed ID: 15384003
    [No Abstract]   [Full Text] [Related]  

  • 18. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
    BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.